valproic acid has been researched along with oligonucleotides in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, J; Wang, G; Wang, L; Xu, XS | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Farrelly-Rosch, A; Lau, CL; Patil, N; Shabanpoor, F; Turner, BJ | 1 |
1 review(s) available for valproic acid and oligonucleotides
| Article | Year |
|---|---|
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
2 other study(ies) available for valproic acid and oligonucleotides
| Article | Year |
|---|---|
Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer.
Topics: Caspase 3; Cell Line, Tumor; Cell Transformation, Neoplastic; Chromatin Immunoprecipitation; Cisplatin; Cyclic AMP Response Element-Binding Protein; DNA-Binding Proteins; Drug Synergism; Gene Silencing; Histone Deacetylases; Humans; Immunohistochemistry; Oligonucleotides; Promoter Regions, Genetic; Repressor Proteins; Sp1 Transcription Factor; Transcription, Genetic; Urinary Bladder Neoplasms; Valproic Acid | 2011 |
Combination of valproic acid and morpholino splice-switching oligonucleotide produces improved outcomes in spinal muscular atrophy patient-derived fibroblasts.
Topics: Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fibroblasts; Humans; Morpholinos; Muscular Atrophy, Spinal; Oligonucleotides; RNA Splicing; Valproic Acid | 2017 |